FACULTY |
Chair:
Francine Foss, MD
Yale University School of Medicine
New Haven, Connecticut, United States
Jasmine Zain, MD
New York University Medical Center
New York, New York, United States
John Zic, MD
Vanderbilt University School of Medicine
Nashville, Tennessee, United States
|
PROGRAM | Module 1 — Concepts in Cutaneous T-Cell Lymphoma: Diagnosis and Treatment
All Faculty
Module 2 — Interactive Clinical Case of a Patient with Early-Stage Mycosis Fungoides
John Zic, MD
Module 3 — Interactive Clinical Case of a Patient with Newly Diagnosed Sézary Syndrome
Francine Foss, MD, PhD
Module 4 — Interactive Clinical Case of a Patient with Mycosis Fungoides Transplant Eligible
Jasmine Zain, MD
|
TARGET AUDIENCE | This educational activity is intended for oncologists, dermatologists, internists, and other healthcare providers, including allied oncology healthcare providers, interested in the management of cutaneous T-cell lymphomas (CTCLs).
|
 STATEMENT OF NEED | Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas characterized by the presence of neoplastic T lymphocytes in the skin. While CTCLs are systemic lymphoproliferative disorders, many of their symptoms manifest cutaneously. Because of the skin’s involvement in these disorders, dermatologists are usually responsible for definitively diagnosing CTCLs, of which there are many types. A recent collaboration by the World Health Organization (WHO) and the European Organization of Research and Treatment of Cancer (EORTC) provided a classification scheme for this spectrum of disorders. The two most common and best studied CTCL variants include mycosis fungoides (MF), an indolent disorder, and Sézary syndrome (SS), a more aggressive disease. Many other types of CTCLs exist that occur infrequently. After establishing diagnosis, dermatologists must then choose initial treatments for patients. For early-stage CTCL, skin-directed therapies are usually the best primary treatment options. For patients with advanced and refractory disease, systemic agents alone or in combination with topical therapies are often required. Often, it may be necessary for dermatologists and oncologists to collaborate and use their overlapping expertise to effectively manage patients with CTCL. Frequently, the best approach to managing CTCL is with such a multidisciplinary team of physicians. This activity helps to fill the educational need for dermatologists and oncologists by exploring the diagnosis and appropriate treatment options for patients with CTCL.
|
LEARNING OBJECTIVES | Upon completion of this educational activity, participants should be able to:
- Identify the symptoms of CTCL that lead to a definitive diagnosis
- Select appropriate topical therapies, phototherapy, and/or radiation therapy for treating patients with CTCL based on disease stage and characteristics
- Indicate when it is appropriate to administer chemotherapies or targeted agents to patients with CTCL
|
DISCLOSURE OF CONFLICTS OF INTEREST |
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:
Dr Foss has disclosed that she has received consulting fees from Allos Therapeutics, Inc. This relationship will not impact her ability to present an unbiased presentation. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Zain has disclosed that she is a member of the scientific advisory boards for Gloucester Pharmaceuticals, Inc; MERCK & CO, Inc; and Therakos, Inc. She has also received fees for non-CME services received directly from a commercial interest or their agents (eg, speakers’ bureaus) from Gloucester, Inc; MERCK & CO, Inc; and Therakos, Inc. None of these relationships will impact her ability to present an unbiased presentation. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Zic has disclosed that he has no real or apparent conflicts of interest to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The following planners and managers of Postgraduate Institute for Medicine, Linda Graham, RN, BSN, BA; Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kirkwood, RN, BSN; and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following planners and managers of prIME Oncology, Janelle Bowersox, RN, MSN, OCN (clinical), Trudy Stoddert, ELS (editorial), and Susan Ahn (project management) hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
DISCLOSURE OF UNLABELED USE |
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Postgraduate Institute for Medicine; prIME Oncology; Eisai, Inc.; and Therakos, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM; prIME Oncology; Eisai, Inc.; and Therakos, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
|
DISCLAIMER | Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|
|
| VIEW MODULESClick here to begin the activity
To participate in this activity, your computer should have a processor the equivalent of Intel Pentium II 450 MHz or faster, with 128MB of RAM and a connection to the internet.
Estimated time to complete activity: 2.75 hours
|
|---|
|
|
|
METHOD OF PARTICIPATION |
Scroll down to
click to view activity
There are no fees for participating and receiving CME credit for this activity. During the period November 2009 through November 30, 2010, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the posttest by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
You may complete the post-test online at
http://www.cmeuniversity.com/Home/tabid/36/Default.aspx
Module 1: ID# 6910
Module 2: ID# 6692
Module 3: ID# 6691
Module 4: ID# 6690
Upon successfully completing the post-test and evaluation, your certificate will be made available immediately.
|
SUPPORTER STATEMENT | This activity is supported by Eisai, Inc. and Therakos, Inc.
|
ENDORSEMENT | This activity is endorsed by the Cutaneous Lymphoma Foundation
|
ACCREDITATION STATEMENT | This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and prIME Oncology. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
|
CREDIT DESIGNATION STATEMENT | Postgraduate Institute for Medicine designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
CONTACT | For questions regarding this activity, please contact:
Postgraduate Institute of Medicine
367 Inverness Parkway
Englewood, Colorado 80112
(303) 799 1930
Email: Information@pimed.com
Web: www.pimed.com |
JOINT SPONSORSHIP | Jointly sponsored by Postgraduate Institute for Medicine and prIME Oncology
|
|
